viewSativa Group PLC

Sativa Group PLC - Professor Page KCL to Medical Advisory Board

RNS Number : 8857S
Sativa Group PLC
11 November 2019

Press Release 


11 November 2019


Sativa Group Plc


("Sativa" or "the Company" or "the Group") 


Professor Clive Page, OBE, BSc, PhD, FSoB, FBPhS,

Professor of Pharmacology at King's College London, appointed to Medical Advisory Board


Sativa Group Plc [NEX: SATI], the UK's leading quoted CBD wellness and medicinal cannabis Group, has appointed Clive Page, Professor of Pharmacology at King's College London, to its Medical Advisory BoardProfessor Page's main research interests are in the pharmacology of inflammation and respiratory disease, and he has published over 300 scientific papers and book chapters.  


He was awarded the Sandoz Prize from the British Pharmacological Society in 1988, The Tanabe Young Investigators Prize from the American College of Clinical Pharmacology in 1996 and the Society of Biology President's Medal in 2012 for "Outstanding Contributions to the Life Sciences".  He is a Fellow of the Royal Society of Biology and an Honorary Fellow of the British Pharmacological Society.  Professor Page was awarded an OBE for "Services to Pharmacology" in 2017.


Dr Nick Horniman, Director of Regulatory Affairs at Sativa, said:  "Professor Page is an eminent research scientist and will add to Sativa's experience, interest and understanding in cannabis based medical products." 


For further information please contact: 


Henry Lees-Buckley 

Chief Executive Officer

Sativa Group Plc 

+44 (0) 20 7971 1255


[email protected]


Joseph Colliver

Chief Financial Officer

Sativa Group Plc 

+44 (0) 20 7971 1255


[email protected] 


NEX Exchange Corporate Adviser


Corporate Finance 


Stephen Keys / Max Gould 

Cenkos Securities plc 

+44 (0) 20 7397 8900

Equity Sales 


Julian Morse

Cenkos Securities

+44 (0) 20 7397 8900

Financial PR and IR


Abchurch Communications

Julian Bosdet

+44 (0)207 4594 4070  

+44 (0) 7771 663 886 



[email protected]




Notes to Editors. 

Sativa Group Plc is the UK's leading quoted CBD wellness and medicinal cannabis group with five operating subsidiaries. 

Goodbody Botanicals provides CBD products online and to retail markets including pharmacies, wellness stores and grocers.  Goodbody Wellness is a high-street retail brand with dedicated CBD wellness stores providing a premium shopping experience to consumers.  Tessellate Collective is a direct-selling network marketing platform servicing consumers at home.  Phytovista laboratories provides independent testing of CBD products to both external customers and fellow Group businesses. 


Sativa Grow holds a Controlled Drug licence and cultivates cannabis plants to fulfil its partnership agreement with King's College London to research the impact of cannabinoids on inflammation and respiratory conditions. 


-     Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Sativa Group PLC

Price: 2.35

Market: AQSE
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Sativa Investments PLC acquires UK-based PhytoVista Laboratories

Geremy Thomas, chief executive of Sativa Investments PLC (AQSE:SATI), tells Proactive's Andrew Scott they've agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000. The British medicinal cannabis investment vehicle will pay £235,000...

on 4/7/18